Here’s a startling fact: Chronic kidney disease has silently climbed the ranks to become a top 10 cause of death worldwide, affecting a staggering 788 million people in 2023—more than double the number in 1990. But here’s where it gets even more alarming: this condition, often overlooked, is not only deadly but also a major driver of heart disease, contributing to 12% of global cardiovascular deaths. So, why isn’t it getting the attention it deserves?
A groundbreaking study led by researchers from NYU Langone Health, the University of Glasgow, and the Institute for Health Metrics and Evaluation (IHME) at the University of Washington has shed light on this growing crisis. Published in The Lancet and presented at the American Society of Nephrology’s Kidney Week, the report reveals that 14% of adults worldwide suffer from chronic kidney disease (CKD). In 2023 alone, 1.5 million people died from it—a 6% increase since 1993, even after adjusting for aging populations.
But here’s the part most people miss: CKD is often symptomless in its early stages, making it a silent killer. By the time symptoms appear, many patients require drastic measures like dialysis, kidney replacement therapy, or transplants. Yet, early intervention through medication and lifestyle changes can prevent these costly and invasive treatments. So, why aren’t we catching it sooner?
The study, part of the Global Burden of Disease (GBD) 2023 initiative, analyzed 2,230 research papers and health datasets from 133 countries. It found that high blood sugar, high blood pressure, and obesity are the leading risk factors. Controversially, despite its prevalence and impact, CKD remains underdiagnosed and undertreated, particularly in low-income regions like sub-Saharan Africa, Southeast Asia, and Latin America, where access to dialysis and transplants is limited.
Dr. Josef Coresh, co-senior author and Director of the Optimal Aging Institute at NYU Langone Health, emphasizes that CKD should be prioritized alongside cancer, heart disease, and mental health by policymakers globally. This May, the World Health Organization took a step in the right direction by adding CKD to its agenda to reduce early deaths from noncontagious diseases by 2030. But is this enough?
Dr. Morgan Grams, co-lead author and Professor of Medicine at NYU Grossman School of Medicine, points out that new medications can slow CKD progression and reduce heart-related risks. However, she warns that underdiagnosis means the true prevalence could be even higher than reported. Here’s a thought-provoking question: If CKD is so widespread and treatable, why aren’t we investing more in early detection and affordable therapies, especially in underserved regions?
This isn’t just a medical issue—it’s a call to action. What do you think? Are we doing enough to tackle this silent epidemic, or is more needed? Share your thoughts in the comments below.
